Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARQ 197 plus irinotecan and cetuximab versus placebo plus irinotecan and cetuximab in wild-type KRAS metastatic colorectal cancer
2009-016025-34Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) comparing ARQ 197 + irinotecan + cetuximab with Placebo + irinotecan + cetuximab (2 arms). Primary endpoint: Progression-free survival. Started Apr 2010; status: completed.
02
Drugs
tivantinib
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2009-016025-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016025-34.